The present disclosure relates to an anti-WT-1/HLA/A2 antibody with enhanced antibody dependent cell-mediated cytotoxicity (ADCC) function due to altered Fc glycosylation. The antibody, which has reduced fucose and/or galactose, was compared to its normally glycosylated counterpart in binding assays,
申请公布号
AU2014346648(A1)
申请公布日期
2016.06.23
申请号
AU20140346648
申请日期
2014.11.07
申请人
NOVARTIS AG;MEMORIAL SLOAN-KETTERING CANCER CENTER;EUREKA THERAPEUTICS, INC.
